AUTHORS
Samon Benrashid, BS, Samantha Teierle2, Shrilekha Misra, PhD3, Rosario Distefano4, Wantong Li, MS5, Alexander He6, Tzung-Huei Lai, PhD7, Ethan C. Whipp8, Arletta Lozanski9, Tzyy-Jye Doong, PhD10, Britten Kalib Gordon, BS11, Jazmin Urrutia12, Mehdi Gharghabi, PharmD13, Andrew D. Mitchell, PhD14, Casey Leimbach15, Shanmugapriya Thangavadivel, PhD16, Deepa Sampath, PhD17, Kerry A. Rogers, MD18, James Stewart Blachly, MD19, Rosa Lapalombella, PhD20, Bradley Blaser, MD21, Cecelia R Miller, PhD22, Jennifer A. Woyach, MD23
AFFILIATIONS
1 The Ohio State University, Columbus, Ohio, United States
2 The Ohio State University, Columbus, Ohio, United States
3 The Ohio State University, Columbus, Ohio, United States
4 The Ohio State University, Columbus, Ohio, United States
5 The Ohio State University, Columbus, Ohio, United States
6 The Ohio State University, Columbus, Ohio, United States
7 The Ohio State University, Columbus, Ohio, United States
8 The Ohio State University, Columbus, Ohio, United States
9 The Ohio State University, Columbus, Ohio, United States
10 The Ohio State University, Columbus, Ohio, United States
11 The Ohio State University, Columbus, Ohio, United States
12 The Ohio State University, Columbus, Ohio, United States
13 The Ohio State University, Columbus, Ohio, United States
14 The Ohio State University, Columbus, Ohio, United States
15 The Ohio State University, Columbus, Ohio, United States
16 The Ohio State University, Columbus, Ohio, United States
17 MD Anderson Cancer Center, Houston, Texas, United States
18 The Ohio State University, Columbus, Ohio, United States
19 The Ohio State University, Columbus, Ohio, United States
20 The Ohio State University, Columbus, Ohio, United States
21 The Ohio State University, Columbus, Ohio, United States
22 The Ohio State University, Columbus, Ohio, United States
23 The Ohio State University, Columbus, Ohio, United States
ABSTRACT
Introduction: A disease-state continuum spans the gap separating chronic lymphocytic leukemia (CLL) and Richter transformation (RT). Prior studies have identified a molecular subtype of RT characterized by whole-genome doubling (WGD), an event thought to occur at the time of RT manifestation. Our group recently reported that WGD may occur during the CLL phase, conferring high likelihood of eventual RT. We posit WGD is an RT-driver arising in the CLL phase and seek to assess how WGD functionally rewires CLL to promote its evolution towards RT.
Methods: We established in vitro models of WGD in CLL using OSUCLL and MEC-1 cell lines by temporary mitotic arrest via treatment with aurora kinase inhibitor AK-01, or CRISPR/Cas9 mediated TP53 knockout. Optical genome mapping (OGM) was performed to observe genomic structural variants (SVs) at early (1) and late (20) passages. Limiting-cell RNA sequencing (lcRNA-seq) and gene set enrichment analysis (GSEA) were utilized to monitor transcriptome changes in at least 3 unique single-cell clones. Protein changes were assessed by immunoblotting. To validate in primary CLL samples, B cells were sorted into WGD+ and WGD- fractions using Hoechst 33342 from time points proximal to clinical WGD notation (t1) and RT diagnosis (t2) for OGM and lcRNA-seq. Single-cell RNA sequencing (scRNA-seq) was performed using peripheral blood mononuclear cells (PBMCs) collected pre-WGD (t0), t1, and t2. Cell cycle perturbations were detected by flow cytometric analysis of Hoechst 33342 staining, and apoptosis assays were performed using annexin V and propidium iodide staining.
Results: WGD induction in cell line models was confirmed by chromosome analysis. OGM revealed a marked increase in SV acquisition both early post-WGD and following 20 passages. Interestingly, SVs present at early passage post-WGD were not always retained at late passage. Using lcRNA-seq, we identified an elevated RT gene expression signature in WGD models, compared to diploid controls. WGD-enriched pathways were predominantly associated with cell cycle regulation, including Myc targets (v1/v2), E2F targets, and G2M checkpoint (p<0.05). Immune signaling pathways were significantly downregulated in WGD cells, including interferon alpha and gamma responses (p<0.05). Primary cell lcRNA-seq analysis (n=6) recapitulated transcriptomic findings from cell lines. scRNA-seq revealed overlapping pseudotimes occupied by B cell populations from early WGD (t1) and RT (t2) timepoints, but not prior to WGD (t0). Immunoblotting revealed heightened expression of key cell cycle drivers polo-like kinase 1 (PLK1) and aurora kinase A (AURKA) (fold change>1.5, p<0.05). Cell cycle analysis suggested inhibition of PLK1, but not AURKA, arrests WGD cells at G2/M and blocks further endoreduplication. Apoptosis assays showed increased cytotoxicity in WGD cells, versus diploid, following PLK1 inhibition (p<0.001), but not AURKA inhibition. Lastly, combinations of a PLK1 inhibitor with venetoclax showed synergistically enhanced cytotoxicity (p<0.05).
Conclusions: Genomic SVs play an important role in RT progression, and our data show early WGD CLL clones rapidly accumulate genomic insults known to drive RT (e.g., MYC, MGA, and CDKN2A/B), prior to lymphomagenesis. Loss of patient-specific SVs within the WGD compartment present pre- and post-WGD points to a clonal specificity underlying which precursor cells undergo and tolerate WGD to establish proliferative progeny. These findings suggest a temporal ordering of events for SV acquisition, as late WGD clones amplified SVs promoting cell survival and growth with fewer de novo SVs in previously unperturbed genomic regions. Transcriptomic analyses support the idea of rapid clonal evolution from CLL, as our data show early WGD progenitors quickly adopt a transcriptional state resembling the cells present at the time of RT. WGD solid tumors develop unique vulnerabilities, and we recapitulate this in CLL with PLK1 inhibition. Although AURKA is a canonical PLK1 activator during mitosis, its inhibition did not demonstrate enhanced cytotoxicity in WGD CLL cells, suggesting essential non-mitotic roles for PLK1 in stabilizing WGD CLL clones. Collectively, these findings provide insight into the genomic and transcriptomic evolution that drives WGD CLL towards an RT profile and identify a novel vulnerability incurred by WGD CLL cells.
DISCLOSURES
Samon Benrashid, BS: No relevant conflicts of interest to declare.